News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018
CAMBRIDGE, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, will report third quarter 2018 financial results after the Nasdaq Global Market closes on Wednesday, October 24, 2018 . Subsequently, at 4:30 p.m.
View HTML
Toggle Summary Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
-- Expands Sarepta’s portfolio to as many as 14 gene therapy programs -- -- Mucopolysaccharidosis type IIIA (MPS IIIA), also called Sanfilippo syndrome type A, is a rare, severe and fatal inherited neurodegenerative lysosomal storage disorder -- -- The pivotal gene therapy study is scheduled to
View HTML
Toggle Summary Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies
-- Partnership significantly expands commercial capacity for Sarepta’s micro-dystrophin gene therapy program, as well as bolsters the Company’s clinical and commercial capacity for its other pipeline programs -- CAMBRIDGE, Mass. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML
Toggle Summary Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder
-- Furthers the Company’s strategy to expand neuromuscular gene therapy franchise --   -- CMT is a group of hereditary, degenerative nerve diseases that in addition to causing extraordinary pain, can greatly impact peripheral motor skills and profoundly limit the ability to walk or use one’s hands
View HTML
Toggle Summary Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy
-- Biopsy of fourth patient showed robust micro-dystrophin expression as measured by Western blot and immunohistochemistry -- -- Positive functional improvements shown across all measures -- -- No serious adverse events (SAEs) observed -- CAMBRIDGE, Mass. , Oct.
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on September 28, 2018 ,
View HTML
Toggle Summary Sarepta Therapeutics and Jerry R. Mendell, M.D. from Nationwide Children’s Hospital to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society
-- Webcast conference call to be held on Thursday, October 4, 2018 at 7:00 a.m. Eastern Time / 8:00 a.m. local Argentina time – CAMBRIDGE, Mass. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and
View HTML
Toggle Summary Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program
CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug
View HTML
Toggle Summary Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen
-- Relying upon Scientific Advisory Group input, Sarepta will seek further scientific advice from European Medicines Agency on a possible path to bring eteplirsen to patients in Europe -- CAMBRIDGE, Mass. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML
Toggle Summary Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony
CAMBRIDGE, Mass. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global biopharmaceutical company focused on the discovery and development of precision genetic medicines for the treatment of rare neuromuscular and other rare diseases, will ring Nasdaq’s Opening
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.